Repository logo
 

GATA6 Cooperates with EOMES/SMAD2/3 to Deploy the Gene Regulatory Network Governing Human Definitive Endoderm and Pancreas Formation.

Published version
Peer-reviewed

Type

Article

Change log

Authors

Chia, Crystal Y 
Denil, Simon LIJ 
Martinez, Iker 
Garcia-Bernardo, Jose 

Abstract

Heterozygous de novo mutations in GATA6 are the most frequent cause of pancreatic agenesis in humans. In mice, however, a similar phenotype requires the biallelic loss of Gata6 and its paralog Gata4. To elaborate the human-specific requirements for GATA6, we chose to model GATA6 loss in vitro by combining both gene-edited and patient-derived pluripotent stem cells (hPSCs) and directed differentiation toward β-like cells. We find that GATA6 heterozygous hPSCs show a modest reduction in definitive endoderm (DE) formation, while GATA6-null hPSCs fail to enter the DE lineage. Consistent with these results, genome-wide studies show that GATA6 binds and cooperates with EOMES/SMAD2/3 to regulate the expression of cardinal endoderm genes. The early deficit in DE is accompanied by a significant reduction in PDX1+ pancreatic progenitors and C-PEPTIDE+ β-like cells. Taken together, our data position GATA6 as a gatekeeper to early human, but not murine, pancreatic ontogeny.

Description

Keywords

GATA6, definitive endoderm, disease modeling, human pluripotent stem cells, pancreatic agenesis, Cell Differentiation, Cell Lineage, Cells, Cultured, Endoderm, GATA6 Transcription Factor, Gene Regulatory Networks, Homeodomain Proteins, Humans, Insulin-Secreting Cells, Pancreas, Pancreatic Diseases, Pluripotent Stem Cells, Protein Binding, Smad2 Protein, Smad3 Protein, T-Box Domain Proteins, Trans-Activators

Journal Title

Stem Cell Reports

Conference Name

Journal ISSN

2213-6711
2213-6711

Volume Title

12

Publisher

Elsevier BV
Sponsorship
Medical Research Council (MC_PC_12009)
We thank the NIHR Cambridge BRC hiPSC core facility for the derivation of GATA6 hiPSC lines, Dr. Norihiro Tsuneyoshi for advice and guidance on gene editing using TALENs, and Dr. Bruno Reversade for insightful discussions. This work was funded by an EDB Singapore Childhood Undiagnosed Diseases Program grant and an A*STAR Strategic Positioning Fund (SPF) Genetic Orphan Diseases Adopted: Fostering Innovation Therapy (GODAFIT) grant and by an ERC starting grant Relieve IMDs and core grant funding from the Wellcome Trust and Medical Research Council (PSAG028) (LV and PM). A.T.H. is a Wellcome Trust Senior Investigator